Differential Expression of αv Integrins in K1735 Melanoma Cells (original) (raw)

Skip Nav Destination

Article navigation

Issue Cover

Research Articles| April 15 1999

Xiaowu Li;

aDepartment of Stomatology, University of California at San Francisco, San Francisco, Calif.;

Search for other works by this author on:

Bing Chen;

aDepartment of Stomatology, University of California at San Francisco, San Francisco, Calif.;

Search for other works by this author on:

Scott D. Blystone;

bDepartments of Anatomy and Cell Biology, State University of New York Health Science Center, Syracuse, N.Y.;

Search for other works by this author on:

Kevin P. McHugh;

cDepartment of Pathology, Washington University School of Medicine, St. Louis, Mo., USA

Search for other works by this author on:

F. Patrick Ross;

cDepartment of Pathology, Washington University School of Medicine, St. Louis, Mo., USA

Search for other works by this author on:

Daniel M. Ramos

aDepartment of Stomatology, University of California at San Francisco, San Francisco, Calif.;

Search for other works by this author on:

Invasion and Metastasis (1999) 18 (1): 1–14.

Content Tools

Abstract

Tumor cell adherence to and migration on the extracellular matrix is an important aspect of cancer progression. This interaction with the extracellular matrix is mediated primarily through the integrin class of cell adhesion molecules. We identified a restricted expression of αvβ3 in highly metastatic K1735M2 and of αvβ5 in poorly metastatic K1735C23 murine melanoma cells. The highly metastatic cells were ten times more motile on vitronectin and fibronectin and approximately three times more invasive through a reconstituted basement membrane than the poorly metastatic cells. This motility was inhibited by addition of anti-β3 antibodies. Injection of the αvβ3-negative K1735C23 cells into syngeneic mice resulted in the generation of a metastatic variant (K1735C23PM) that neo expressed the αvβ3 complex, indicating that expression of αvβ3 is required for K1735 melanoma metastasis. Injection of highly metastatic K1735M2 cells in the presence of blocking antibody to β3 reduced tumor size by approximately 80%. Treatment of the K1735M2 cells with a retroviral antisense β3 construct significantly reduced their expression of αvβ3 and also reduced their motility on extracellular matrix ligands and their invasion through a reconstituted basement membrane. In contrast, when the K1735C23 cells were treated with a construct containing the full-length β3 cDNA, their motility on extracellular matrix proteins and invasion of a reconstituted basement membrane were significantly increased. These results indicate that αvβ3 is required for migration and invasion of K1735 melanoma cells in vitro and primary tumor growth and metastasis in vivo.

This content is only available via PDF.

1999

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

You do not currently have access to this content.

Sign in

Digital Version

Pay-Per-View Access

$45.00

1 Karger Article Bundle Token

$170

Rental

This article is also available for rental through DeepDyve. Read this now at DeepDyve